Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Rev. Ciênc. Plur ; 7(2): 74-87, maio 2021. tab
Article in Portuguese | BBO, LILACS | ID: biblio-1282740

ABSTRACT

Introdução:Os trabalhadores em saúde mental são expostos a situações adversas e estressantes, agravadas por um constante estado de excitabilidade e atenção, sendo conhecido aumento na incidência da Sídrome de Burnout e de ansiedade nesse grupo.Objetivo:avaliar a prevalência da Síndrome na amostra e suas correlações com outras variáveis.Metodologia:Estudo transversal, observacional, onde 142 trabalhadores de um hospital psiquiátrico foram entrevistados por meio de três questionários: sociocultural, Maslach Burnout Inventory eBeck Anxiety Inventory. Os dados foram tabulados e analisados por meio do teste de qui-quadrado, com valor de p significativo <0,05.Resultados:na amostra, a maioria era mulher, com média de idade 50 anos e média de 14 anos de trabalho nesse hospital. 55 trabalhadores apresentaram Burnout (pelo menos um critério comprometido), sendo 18 com diminuição da esfera de realização pessoal, 41 com exaustão emocionale 23 sofrendo de despersonalização. Foi encontrada uma relação da Síndrome de Burnout com elevados níveis de ansiedade (p=0.0008). Conclusões:O grupo com maiores níveis de ansiedade mostraram pior estados emocional e de saúde mental, associado à incidência da Síndrome de Burnout (AU).


Introduction:Mental health workers are exposed to adverse and stressful situations, aggravated by a constant state of excitability and attention, with an increase in the incidence of Burnout Syndrome and anxiety in this group.Objective:to evaluate the prevalence of the Syndromein the sample and its correlations with other variables.Methodology:Cross-sectional, observational study, where 142 workers from a psychiatric hospital were interviewed using three questionnaires: sociocultural, Maslach Burnout Inventory and Beck Anxiety Inventory. The data were tabulated and analyzed using the chi-square test, with a significant p-value <0.05.Results:in the sample, most were women, with an average age of 50 years and an average of 14 years of work at this hospital. 55 workers had Burnout (at least one compromised criterion), 18 with reduced personal achievement, 41 with emotional exhaustion and 23 suffering from depersonalization. A relationship between Burnout Syndrome and high levels of anxiety was found (p = 0.0008). Conclusions:The group with the highest levels of anxiety showed worse emotional and mental health states, associated with the incidence of Burnout Syndrome (AU).


Introducción: Los trabajadores de salud mental están expuestos a situaciones adversas y estresantes, agravadas por un estado constante de excitabilidad y atención, con un aumento de la incidencia del Síndrome de Burnout y ansiedad en este grupo.Objetivo: evaluar la prevalencia de la Síndromeen la muestra y sus correlaciones con otras variables. Metodología: Estudio observacional transversal, en el que se entrevistó a 142 trabajadores de un hospital psiquiátrico mediante tres cuestionarios: sociocultural, Maslach Burnout Inventory y Beck Anxiety Inventory. Los datos se tabularon y analizaron mediante la prueba de chi-cuadrado, con un valor de p significativo <0,05. Resultados: en la muestra, la mayoría eran mujeres, con una edad media de 50 años y una media de 14 años de trabajo en este hospital. 55 trabajadores tenían Burnout (al menos un criterio comprometido), 18 con logro personal reducido, 41 con agotamiento emocional y 23 con despersonalización. Se encontró relación entre el Síndrome de Burnout y altos niveles de ansiedad (p = 0,0008). Conclusiones: El grupo con mayores niveles de ansiedad presentó peoresestados emocionales y de salud mental, asociados a la incidencia del Síndrome de Burnout (AU).


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Anxiety/psychology , Stress, Psychological/psychology , Mental Health , Health Personnel/psychology , Burnout, Psychological/psychology , Public Policy , Brazil , Chi-Square Distribution , Epidemiology, Descriptive , Cross-Sectional Studies/methods , Surveys and Questionnaires , Hospitals, Psychiatric
4.
Adv Rheumatol ; 61: 15, 2021. tab, graf
Article in English | LILACS | ID: biblio-1152741

ABSTRACT

Abstract Background: Systemic sclerosis (SSc) Is a clinically complex and challenging disease, that leads to skin fibrosis. Its most frequent complication is interstitial lung disease (ILD), which leads to a worse prognosis. In this situation, cyclophosphamide is considered the gold standard for its treatment, despite the controversies regarding its efficacy and toxicity. However, studies using rituximab (RTX) have shown that this drug may be a promising therapeutic option. Objectives: This paper objective was to analyze the scientific evidence on the RTX effects on SSc. Methods: A systematic review (SR) was performed including clinical trials (CTs) on the use of RTX in SSc, published up to May 2020. The studies were identified through systematic searches in bibliographic databases using a predefined search strategy. The following databases were used: PUBMED, SCOPUS, SCIELO, LILACS, SCIENCE DIRECT, WEB OF SCIENCE, COCHRANE, WHOLIS, PAHO and EMBASE. Also, a manual search was performed. The methodological quality of the studies was determined using Jadad scale, Risk of Bias Tool (RoB 2.0) and Risk of Bias in Non-Randomized Studies - of Interventions tool (ROBINS-I). A meta-analysis of the randomized CTs was performed, using Review Manager. Results: Ten CTs were included in this SR. Of these, three were randomized and seven were non-randomized. Five showed a statistically significant improvement in forced vital capacity (FVC) at some time during follow-up. Regarding the skin, eight studies showed statistically significant improvements according toa the modified Rodnan skin score. The meta-analysis found positive effects of RTX in SSc, with a statistical significance for lung disease. Conclusion: Rituximab is a promising strategy for the SSc-associated ILD and cutaneous fibrosis treatment. PROSPERO registration number: CRD42019132018.(AU)


Subject(s)
Humans , Scleroderma, Systemic/drug therapy , Rituximab/therapeutic use , Prognosis , Cyclophosphamide/adverse effects , Cyclophosphamide/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL